MedPath

Ropivacaine Use in Femoral Nerve Block; What is the Minimal Effective Analgesic Concentration (MEAC 90)

Phase 4
Conditions
Postoperative Pain
Registration Number
NCT04834440
Lead Sponsor
Healthpoint Hospital
Brief Summary

The aim of this study is to determine the minimal effective ropivacaine concentration required to provide adequate analgesic femoral nerve block in 90% of patients (MEAC90)

Detailed Description

* Before induction of GA, all patients will receive sciatic, obturator, lateral femoral cutaneous and femoral nerve blocks.

* The femoral nerve block will be performed using 15ml of ropivacaine which concentration relied on the response of the previous patient.

* Based on biased-coin design up-down sequential method: when a patient has a negative response, the next patient will receive a concentration 0.01% w/v higher. However if he has a positive response, the next patient will be randomized to receive either the same ropivacaine concentration or a concentration 0.01% w/v less.

* Patients with pain free recovery will be considered to have positive response.

* Patients' responses will be analyzed to calculate the MEAC90

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
45
Inclusion Criteria
  • Patients, who are scheduled for knee ligament reconstruction
Exclusion Criteria
  • <18 y,

  • ASA physical class greater >III

    • BMI >40 has any contraindication for medications or techniques used in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
effective analgesic femoral nerve blockin recovery unit (one hour after surgery)

postoperative pain. it will be assessed using numerical rating scale (NRS). NRS, 0 = no pain; 10 = worst pain imaginable; if NRS ≥ 3, pain (ineffective block) is considered, other wise a successful block will be considered.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Healthpoint Hospital

🇦🇪

Abu Dhabi, United Arab Emirates

© Copyright 2025. All Rights Reserved by MedPath